JOINN Laboratories Q3 2026: Bookings Double, Profit Up Tenfold — the Preclinical CRO Thermometer Heats Up Again

On the evening of 28 October 2026, JOINN Laboratories (603127.SH / 06127.HK) reported nine-month revenue of RMB 1.188B (+20.60%) and net profit of RMB 930M (+1051.94%), with Q3 revenue of RMB 484M (+53.01%). The order book matters more: cumulative new bookings of about RMB 3.42B (+109%), including RMB 1.4B in Q3 alone (+126%), and a backlog of about RMB 4.5B (+80%). As the front end of the R&D spending chain, preclinical safety evaluation is flashing a clear recovery signal — the last link in the industry's transmission chain to turn.

On the evening of 28 October 2026, preclinical CRO leader JOINN Laboratories (603127.SH / 06127.HK) released its Q3 2026 report. Nine-month revenue reached RMB 1.188B, up 20.60% year on year; net profit attributable to shareholders was RMB 930M, up a striking 1051.94%; non-IFRS-basis (deducted) net profit was RMB 881M, up 2933.08%. Q3 alone delivered revenue of RMB 484M (+53.01%) and net profit of RMB 182M (+821.27%). The market reacted immediately: the stock closed at RMB 46.85 on 28 October, up 7.55% in a day.

But the real story sits in the order book, not the income statement. For a CRO, new bookings lead revenue recognition — a signed project takes months, sometimes years, to flow through scheduling, study conduct and revenue recognition. The wider the gap between booking growth and revenue growth, the higher the revenue visibility for the next couple of years.

Bookings lead: +109% new signings against +20.6% revenue

Cumulative new bookings for the first three quarters reached about RMB 3.42B, up 109% year on year. Q3 alone contributed about RMB 1.4B, up 126% year on year and 26.1% quarter on quarter. The backlog at quarter-end stood at about RMB 4.5B, up 80%.

Set this against the revenue line: nine-month revenue of RMB 1.188B grew 20.6%, and Q3 revenue of RMB 484M grew 53.0%. Bookings are growing roughly five times faster than revenue. That is not an anomaly; it is how the industry works. The pricing and scheduling pent up during the 2023-2024 downturn is being released as orders in one burst, while revenue will recognise project by project over the following quarters.

Heyuan Biopharma, which reported the same evening, and Pharmaron before it each used a variation of the same phrase: industry demand recovery and a marked increase in market need. Western Securities' note singled out JOINN's Q3 bookings as having doubled year on year — the last time preclinical safety evaluation bookings grew at this magnitude was 2021.

Where the profit elasticity comes from: RMB 866M fair value plus a laboratory turnaround

Of the RMB 930M net profit, about RMB 866M came from fair-value changes in biological assets — roughly 93% of the total. This is a quirk of JOINN's financial model: the company holds large populations of laboratory primates whose book values are re-marked to market. In 2023-2024, falling macaque prices made this line a drag; in 2026, as prices recovered, it became an amplifier.

Strip out the fair-value swings and the operating picture improves too: laboratory services and other businesses contributed about RMB 15M of net profit in the first three quarters, against a RMB 111M loss a year earlier — a genuine turnaround in the core business. Operating cash flow of RMB 853M, up 220.3%, confirmed the quality of the recovery alongside the bookings surge.

The fair-value line is double-edged: it makes quarterly profit swings enormous and non-extrapolatable. The right way to read JOINN's trend is the trio of laboratory-business turnaround, doubled bookings and positive cash flow — not the headline profit growth number.

The primate cycle turns: from cost line back to profit line

Laboratory primates are a hard capacity constraint for safety evaluation. The scarcity of 2022 pushed leading CROs to stock up at high prices; the subsequent price retreat produced impairment and fair-value losses in sequence. The 2026 recovery mirrors the full cycle: rising prices improve revaluation gains and signal full safety-evaluation schedules — after all, animal usage is the most physical indicator of demand.

For downstream clients this is equally positive: tightening preclinical capacity and rising prices usually accompany an acceleration in IND filings. It cross-checks with WuXi AppTec's Q3 disclosure that its safety evaluation business grew 40.6% in revenue — the preclinical demand recovery is industry-wide, not a single-company beta.

Editor's view: the last link in the transmission chain

Our recent roundup of the four A-share CDMO leaders showed the manufacturing backend recovering: WuXi AppTec revenue +38.6%, Asymchem emerging business +50%, Pharmaron bookings +30%. JOINN's report completes the chain at its very front end — preclinical research. When the earliest-stage bookings double, it means total R&D investment is expanding, not merely that existing programmes are migrating downstream.

The transmission order is worth noting: financing recovery → preclinical bookings (JOINN, +109%) → CDMO signings (WuXi +60%, Pharmaron +30%, Asymchem +30%) → late-stage and commercial revenue ramp (WuXi small-molecule D&M +65.6%). Preclinical is the most sensitive and earliest-turning link in this chain. Its re-warming is the final piece of the H2 2026 CXO upcycle narrative.